149
Views
7
CrossRef citations to date
0
Altmetric
Case Report

Management for Residual Ground-Glass Opacity Lesions After Resection of Main Tumor in Multifocal Lung Cancer: A Case Report and Literature Review

ORCID Icon, , , ORCID Icon, , ORCID Icon, , , , , & show all
Pages 977-985 | Published online: 03 Feb 2021

References

  • Park CM, Goo JM, Lee HJ, Lee CH, Chun EJ, Im J-G. Nodular ground-glass opacity at thin-section CT: histologic correlation and evaluation of change at follow-up. Radiographics. 2007;27(2):391–408. doi:10.1148/rg.27206506117374860
  • Detterbeck FC, Marom EM, Arenberg DA, et al. The IASLC lung cancer staging project: background data and proposals for the application of TNM staging rules to lung cancer presenting as multiple nodules with ground glass or lepidic features or a pneumonic type of involvement in the Forthcoming Eighth Edition of the TNM classification. J Thoracic Oncol. 2016;11:666–680.
  • Shimada Y, Saji H, Otani K, et al. Survival of a surgical series of lung cancer patients with synchronous multiple ground-glass opacities, and the management of their residual lesions. Lung Cancer (Amsterdam, Netherlands). 2015;88:174–180.
  • Jiang G, Xie D. [Early-stage lung cancer manifested as ground-glass opacity]. Zhonghua Wai Ke Za Zhi [Chinese Journal of Surgery]. 2015;53:790–793. Chinese.
  • Kim HK, Choi YS, Kim J, Shim YM, Lee KS, Kim K. Management of multiple pure ground-glass opacity lesions in patients with bronchioloalveolar carcinoma. J Thoracic Oncol. 2010;5:206–210.
  • Loukeri AA, Kampolis CF, Ntokou A, Tsoukalas G, Syrigos K. Metachronous and synchronous primary lung cancers: diagnostic aspects, surgical treatment, and prognosis. Clin Lung Cancer. 2015;16:15–23.25246383
  • Kozower BD, Larner JM, Detterbeck FC, Jones DR. Special treatment issues in non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143:e369S–e399S.23649447
  • Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–247.19097774
  • Chang B, Hwang JH, Choi Y-H, et al. Natural history of pure ground-glass opacity lung nodules detected by low-dose CT scan. Chest. 2013;143:172–178.22797081
  • Tamura M, Shimizu Y, Yamamoto T, Yoshikawa J, Hashizume Y. Predictive value of one-dimensional mean computed tomography value of ground-glass opacity on high-resolution images for the possibility of future change. J Thoracic Oncol. 2014;9(4):469–472. doi:10.1097/JTO.0000000000000117
  • Lee SW, Leem C-S, Kim TJ, et al. The long-term course of ground-glass opacities detected on thin-section computed tomography. Respir Med. 2013;107:904–910.23514949
  • Li M, Wu N, Zhang L, et al. Solid component proportion is an important predictor of tumor invasiveness in clinical stage TNM (cTNM) lung adenocarcinoma. Cancer Imaging. 2018;18:18.29728140
  • Migliore M, Fornito M, Palazzolo M, et al. Ground glass opacities management in the lung cancer screening era. Ann Transl Med. 2018;6:90.29666813
  • Kobayashi Y, Mitsudomi T. Management of ground-glass opacities: should all pulmonary lesions with ground-glass opacity be surgically resected? Transl Lung Cancer Res. 2013;2:354–363.25806254
  • Dai C, Ren Y, Xie H, et al. Clinical and radiological features of synchronous pure ground-glass nodules observed along with operable non-small cell lung cancer. J Surg Oncol. 2016;113:738–744.27041153
  • Gao RW, Berry MF, Kunder CA, et al. Survival and risk factors for progression after resection of the dominant tumor in multifocal, lepidic-type pulmonary adenocarcinoma. J Thorac Cardiovasc Surg. 2017;154.
  • Cho S, Yang H, Kim K, Jheon S. Pathology and prognosis of persistent stable pure ground-glass opacity nodules after surgical resection. Ann Thorac Surg. 2013;96:1190–1195.23968760
  • Shimada Y, Maehara S, Kudo Y, et al. Profiles of lung adenocarcinoma with multiple ground-glass opacities and the fate of residual lesions. Ann Thorac Surg. 2020;109:1722–1730.32057816
  • Sun X, Li Y, Zhu Y, et al. Four-year follow-up outcomes after stereotactic body radiation therapy for central early-stage non-small cell lung cancer. Transl Lung Cancer Res. 2020;9:1472–1482.32953519
  • Eriguchi T, Takeda A, Sanuki N, et al. Stereotactic body radiotherapy for operable early-stage non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 2017;109:62–67.
  • Finley DJ, Yoshizawa A, Travis W, et al. Predictors of outcomes after surgical treatment of synchronous primary lung cancers. J Thoracic Oncol. 2010;5:197–205.
  • Zhang Y, Deng C, Ma X, et al. Ground-glass opacity-featured lung adenocarcinoma has no response to chemotherapy. J Cancer Res Clin Oncol. 2020;146:2411–2417.32356178
  • Lu W, Cham QL, Wang J, et al. The impact of chemotherapy on persistent ground-glass nodules in patients with lung adenocarcinoma. J Thorac Dis. 2017;9:4743–4749.29268545
  • Mok TSK, Wu Y-L, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, Phase 3 trial. Lancet (London, England). 2019;393:1819–1830.
  • Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in Stage III NSCLC. N Engl J Med. 2018;379:2342–2350.30280658
  • Wu F, Li W, Zhao W, et al. Synchronous ground‐glass nodules showed limited response to anti‐PD‐1/PD‐L1 therapy in patients with advanced lung adenocarcinoma. Clin Transl Med. 2020;10.31993801
  • Liang H, Deng H, Liang W, et al. Perioperative chemoimmunotherapy in a patient with stage IIIB non-small cell lung cancer. Ann Transl Med. 2020;8:245.32309392
  • Ye C, Wang J, Li W, Chai Y. Novel strategy for synchronous multiple primary lung cancer displaying unique molecular profiles. Ann Thorac Surg. 2016;101:e45–e47.26777970
  • Wu Y-L, Tsuboi M, He J, et al. Osimertinib in resected EGFR-mutated non–small-cell lung cancer. N Engl J Med. 2020.
  • Zhong W-Z, Wang Q, Mao W-M, et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. Lancet Oncol. 2018;19:139–148.29174310
  • Yue D, Xu S, Wang Q, et al. Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, Phase 2 trial. Lancet Respir Med. 2018;6:863–873.30150014
  • Ettinger DSWD, Aggarwal C NCCN Clinical Practice Guidelines in Oncology: non-Small Cell Lung Cancer. Version 2.2021. 2020.
  • Takenaka T, Yano T, Ito K, et al. Biological significance of the maximum standardized uptake values on positron emission tomography in non-small cell lung cancer. J Surg Oncol. 2009;100:688–692.19731260
  • Shao X, Niu R, Jiang Z, Shao X, Wang Y. Role of PET/CT in Management of early lung adenocarcinoma. AJR Am J Roentgenol. 2020;214:437–445.31714848
  • Kim TJ, Park CM, Goo JM, Lee KW. Is there a role for FDG PET in the management of lung cancer manifesting predominantly as ground-glass opacity? AJR Am J Roentgenol. 2012;198:83–88.22194482
  • Wu HB, Wang L, Wang QS, et al. Adenocarcinoma with BAC features presented as the nonsolid nodule is prone to be false-negative on 18F-FDG PET/CT. Biomed Res Int. 2015;2015:243681.25879020
  • Liang W, Zhao Y, Huang W, et al. Non-invasive diagnosis of early-stage lung cancer using high-throughput targeted DNA methylation sequencing of circulating tumor DNA (ctDNA). Theranostics. 2019;9:2056–2070.31037156
  • Baisi A, Raveglia F, Cioffi U. Preoperative positron emission tomography/computed tomography in pulmonary ground glass opacities: a useful diagnostic and staging tool or not? J Thorac Cardiovasc Surg. 2016;151:279–280.26699783
  • Wang L, Wu C, Qiao L, et al. Clinical significance of folate receptor-positive circulating tumor cells detected by ligand-targeted polymerase chain reaction in lung cancer. J Cancer. 2017;8:104–110.28123603
  • Chen X, Zhou F, Li X, et al. Folate receptor-positive circulating tumor cell detected by LT-PCR-based method as a diagnostic biomarker for non-small-cell lung cancer. J Thorac Oncol. 2015;10:1163–1171.26200270
  • Xue Y, Cong W, Xie S, Shu J, Feng G, Gao H. Folate-receptor-positive circulating tumor cells as an efficacious biomarker for the diagnosis of small pulmonary nodules. J Cancer Res Ther. 2018;14:1620–1626.30589049
  • Zhou Q, Geng Q, Wang L, et al. Value of folate receptor-positive circulating tumour cells in the clinical management of indeterminate lung nodules: a non-invasive biomarker for predicting malignancy and tumour invasiveness. EBioMedicine. 2019;41:236–243.30872130
  • Yu Y, Chen Z, Dong J, et al. Folate receptor-positive circulating tumor cells as a novel diagnostic biomarker in non-small cell lung cancer. Transl Oncol. 2013;6:697–702.24466372
  • Jiang T, Zhao J, Zhao C, et al. Dynamic monitoring and predictive value of circulating tumor cells in EGFR-mutated advanced non-small-cell lung cancer patients treated with first-line EGFR tyrosine kinase inhibitors. Clin Lung Cancer. 2019;20:124–133e122.30587399